FDA Issues Policy For Making Immediate Changes To Device Submission Guidelines
This article was originally published in The Gray Sheet
Executive Summary
CDRH has posted a final standard operating procedure to describe how it will rapidly inform stakeholders of changes to expectations for new device submissions in the form of “Level 1, Immediately-in-Effect” guidance documents.
You may also be interested in...
FDA Puts Black Box Warning On Power Morcellators With Immediately-In-Effect Guidance
FDA has followed through on the advice of its advisory panel by requiring new labeling for power morcellators used to treat uterine fibroids, emphasizing the procedure’s potential to spread cancer. FDA wants to restrict the power morcellation procedure to younger women who are interested in maintaining their ability to have children and who have been thoroughly informed of the risks.
Is Draft Guidance More Than Meets The Eye? Senators Seek Answers From FDA
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
CDRH Tries Again On Proposal For Rapidly Communicating Policy Changes
FDA’s device center has dropped previously proposed “notice-to-industry letter” terminology and abandoned the idea of sending out rapid-fire communications in anything but official guidance format in its new draft standard operating procedures on “Level 1 – immediately in effect” guidance. The document updates a 2011 SOP that faced pushback from companies.